Correlation Between BridgeBio Pharma and Denali Therapeutics
Can any of the company-specific risk be diversified away by investing in both BridgeBio Pharma and Denali Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BridgeBio Pharma and Denali Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between BridgeBio Pharma and Denali Therapeutics, you can compare the effects of market volatilities on BridgeBio Pharma and Denali Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BridgeBio Pharma with a short position of Denali Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of BridgeBio Pharma and Denali Therapeutics.
Diversification Opportunities for BridgeBio Pharma and Denali Therapeutics
-0.03 | Correlation Coefficient |
Good diversification
The 3 months correlation between BridgeBio and Denali is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding BridgeBio Pharma and Denali Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Denali Therapeutics and BridgeBio Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BridgeBio Pharma are associated (or correlated) with Denali Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Denali Therapeutics has no effect on the direction of BridgeBio Pharma i.e., BridgeBio Pharma and Denali Therapeutics go up and down completely randomly.
Pair Corralation between BridgeBio Pharma and Denali Therapeutics
Given the investment horizon of 90 days BridgeBio Pharma is expected to under-perform the Denali Therapeutics. In addition to that, BridgeBio Pharma is 1.0 times more volatile than Denali Therapeutics. It trades about -0.05 of its total potential returns per unit of risk. Denali Therapeutics is currently generating about -0.02 per unit of volatility. If you would invest 2,559 in Denali Therapeutics on September 7, 2024 and sell it today you would lose (227.00) from holding Denali Therapeutics or give up 8.87% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
BridgeBio Pharma vs. Denali Therapeutics
Performance |
Timeline |
BridgeBio Pharma |
Denali Therapeutics |
BridgeBio Pharma and Denali Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with BridgeBio Pharma and Denali Therapeutics
The main advantage of trading using opposite BridgeBio Pharma and Denali Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BridgeBio Pharma position performs unexpectedly, Denali Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Denali Therapeutics will offset losses from the drop in Denali Therapeutics' long position.BridgeBio Pharma vs. Blueprint Medicines Corp | BridgeBio Pharma vs. Amylyx Pharmaceuticals | BridgeBio Pharma vs. Day One Biopharmaceuticals | BridgeBio Pharma vs. Terns Pharmaceuticals |
Denali Therapeutics vs. Stoke Therapeutics | Denali Therapeutics vs. Black Diamond Therapeutics | Denali Therapeutics vs. 4D Molecular Therapeutics | Denali Therapeutics vs. Ascendis Pharma AS |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Complementary Tools
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |